EGFR and neoplasm: Additionally, helical domain mutations are often associated with early-stage colorectal cancers, but they have also been linked to tumor resistance to certain therapies, such as anti-EGFR monoclonal antibodies, due to the persistent activation of downstream signaling pathways (Fu et al., 2021).